Compass Therapeutics (CMPX) EBIAT (2023 - 2025)
Historic EBIAT for Compass Therapeutics (CMPX) over the last 3 years, with Q3 2025 value amounting to -$14.3 million.
- Compass Therapeutics' EBIAT fell 3604.62% to -$14.3 million in Q3 2025 from the same period last year, while for Sep 2025 it was -$65.8 million, marking a year-over-year decrease of 3778.76%. This contributed to the annual value of -$49.4 million for FY2024, which is 1619.29% down from last year.
- According to the latest figures from Q3 2025, Compass Therapeutics' EBIAT is -$14.3 million, which was down 3604.62% from -$19.9 million recorded in Q2 2025.
- Compass Therapeutics' EBIAT's 5-year high stood at -$7.8 million during Q1 2023, with a 5-year trough of -$19.9 million in Q2 2025.
- Its 3-year average for EBIAT is -$13.0 million, with a median of -$13.1 million in 2024.
- In the last 5 years, Compass Therapeutics' EBIAT crashed by 518.87% in 2024 and then plummeted by 5419.49% in 2025.
- Quarter analysis of 3 years shows Compass Therapeutics' EBIAT stood at -$13.4 million in 2023, then decreased by 12.06% to -$15.0 million in 2024, then grew by 5.15% to -$14.3 million in 2025.
- Its EBIAT stands at -$14.3 million for Q3 2025, versus -$19.9 million for Q2 2025 and -$16.6 million for Q1 2025.